Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.44 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | MMP9 | P14780 | 2/20 | 0.40 |
| ▸ | MMP13 | P45452 | 2/20 | 0.40 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.40 |
| ▸ | MMP1 | P03956 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28122613 | 1.00 | MCHR1 (0.44) | MCHR1PLA2G2CCNR2ALDH1A1NR1I2 | |
| SCHEMBL16039239 | 0.94 | CA2 (0.42) | MCHR1PLA2G2CCNR2ALDH1A1CA12 | |
| SCHEMBL1545377 | 0.88 | CA2 (0.47) | ALDH1A1CA12CA2CA9MMP9 | |
| SCHEMBL1545434 | 0.88 | CA2 (0.47) | ALDH1A1CA12CA2CA9MMP9 | |
| SCHEMBL1545381 | 0.88 | CA2 (0.47) | ALDH1A1CA12CA2CA9MMP9 | |
| SCHEMBL5151398 | 0.85 | TDP1 (0.43) | ALDH1A1MMP9MMP13MMP1TDP1 | |
| SCHEMBL5279498 | 0.85 | MCHR1 (0.47) | MCHR1PLA2G2CCNR2ALDH1A1NR1I2 | |
| SCHEMBL3086955 | 0.85 | MCHR1 (0.47) | MCHR1PLA2G2CCNR2ALDH1A1NR1I2 | |
| SCHEMBL15272323 | 0.85 | MCHR1 (0.47) | MCHR1PLA2G2CCNR2ALDH1A1NR1I2 | |
| SCHEMBL5902719 | 0.85 | MCHR1 (0.47) | MCHR1PLA2G2CCNR2ALDH1A1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7833993-B2 | Immunomodulatory compounds and methods of use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| EP-1439184-B1 | Immunological adjuvant compounds | EISAI R&D MAN CO LTD (JP) | 2010-06-16 | — | — | EP | disclosed |
| US-7560584-B2 | Immunomodulatory compounds and methods of use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-07-14 | — | — | US | disclosed |
| EP-2039361-A2 | Use of immunomodulatory compounds | Eisai R&D Management Co., Ltd. (JP) | 2009-03-25 | — | — | EP | disclosed |
| EP-1511499-B1 | IMMUNOMODULATORY COMPOUNDS AND METHODS OF USE THEREOF | EISAI R&D MAN CO LTD (JP) | 2008-12-03 | — | — | EP | disclosed |
| US-20050164988-A1 | Immunomodulatory compounds and methods of use thereof | EISAI CO., LTD. (JP) | 2005-07-28 | — | — | US | disclosed |
| US-20050123566-A1 | Immunomodulatory compounds and methods of use thereof | EISAI CO., LTD (JP) | 2005-06-09 | — | — | US | disclosed |
| US-6835721-B2 | Phosphate or ammonium compounds that function as immunological adjuvants when co-administered with antigens such as vaccines for bacterial and viral diseases | EISAI CO., LTD. (JP) | 2004-12-28 | — | — | US | disclosed |
| EP-1439184-A1 | Immunological adjuvant compounds | Eisai Co., Ltd. (JP) | 2004-07-21 | — | — | EP | disclosed |
| EP-1147117-B1 | IMMUNOLOGICAL ADJUVANT COMPOUNDS | EISAI CO LTD (JP) | 2004-06-16 | — | — | EP | disclosed |
| US-20040006242-A1 | Immunomodulatory compounds and method of use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-01-08 | — | — | US | disclosed |
| US-20030153532-A1 | Immunomodulatory compounds and methods of use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2003-08-14 | — | — | US | disclosed |
| US-6551600-B2 | A phosphate derivative when co-administered with antigens such as vaccines for bacterial and viral diseases function as immunological adjuvant | EISAI CO., LTD. (JP) | 2003-04-22 | — | — | US | disclosed |
| US-20020176861-A1 | Immunological adjuvant compounds compositions and methods of use thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2002-11-28 | — | — | US | disclosed |
| EP-1147117-A1 | IMMUNOLOGICAL ADJUVANT COMPOUNDS | Eisai Co., Ltd. (JP) | 2001-10-24 | — | — | EP | disclosed |
| US-6290973-B1 | VACCINES FOR BACTERIAL AND VIRAL DISEASES | EISAI CO., LTD. (JP) | 2001-09-18 | — | — | US | disclosed |
| WO-2000044758-A1 | IMMUNOLOGICAL ADJUVANT COMPOUND | EISAI CO., LTD. (JP) | 2000-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050123566-A1 | Immunomodulatory compounds and methods of use thereof | TLR5, TLR3, TLR6 | MCHR1 2418/4885PLA2G2C 230/4885CNR2 1164/4885 |
| US-20020176861-A1 | Immunological adjuvant compounds compositions and methods of use thereof | TLR5, MYD88, TLR3 | MCHR1 2944/4885PLA2G2C 61/4885CNR2 2154/4885 |
| US-20050164988-A1 | Immunomodulatory compounds and methods of use thereof | TSLP, IL5, ICOS | MCHR1 2495/4885PLA2G2C 600/4885CNR2 317/4885 |
| US-20040006242-A1 | Immunomodulatory compounds and method of use thereof | IL5, ICOS, TSLP | MCHR1 2434/4885PLA2G2C 679/4885CNR2 326/4885 |
| US-20030153532-A1 | Immunomodulatory compounds and methods of use thereof | TLR5, TLR3, TLR6 | MCHR1 2418/4885PLA2G2C 230/4885CNR2 1164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.